Re: Eversana ValuationCaseStudy
in response to
by
posted on
Jan 08, 2022 12:52PM
Buck, please don't feel "Sorry if this seems negative, just being honest" from my perspective.
To me the entire point of posting is to share ideas and to try to gain some sanity about RVX and ZCC from an investor's perspective. This is not a healthy or even reasonable situation for a biotech with a BTD from the FDA for apabetalone.
My feeling with regards to Hepa taking control if Don doesn't pull a rabbit out of a hat is that Hepa will have to look after Eastern. I don't know what that might look like but if they have to be fair to all shareholders then, it could be, we may make a buck to two depending on what you got in at. I was expecting a pot of gold.
I don't think any poster should apologize for being analytical and critical. Afterall, we've all watched our investments be squandered through dilution and bad deals for at least 11 years despite continuing positive science.
GLTA
Toinv